20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Pfizer (NYSE: PFE) announces its next round of earnings this Tuesday, August 2, 2011. Here is Benzinga's everything-that-matters guide for this Tuesday's second quarter earnings announcement.
Earnings and Revenue:
Based on estimates, investors are readying for a positive EPS reading of 59 cents per share and revenues of $16.98 billion. Investors will be keen to see how this quarter's numbers stack up against the year-ago quarter's positive EPS of 62 cents per share on revenues of $17.32 billion. Investors are bracing themselves for Tuesday when we'll learn if Pfizer reports expected declines in both EPS and revenue from the year-ago quarter.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 | Q4 | Q3 | Q2 |
| EPS Estimate | $0.58 | $0.46 | $0.51 | $0.52 |
| EPS Actual | $0.60 | $0.47 | $0.54 | $0.62 |
Stock Performance:
Shares of Pfizer were trading at $19.30 as of July 27, 2011. Shares are up 12.5% year to date. For a full 12 months, the return has risen by 15.7%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
- Long-term shareholders are already enjoying 12-month gains prior to the announcement
Average Stock Rating:
The average rating by analysts for Pfizer is a Moderate Buy. The strength of this rating has declined slightly over the past three months.
Competitors:
Want to check out the performance of Pfizer closest competitors? Take a look at some of the company's peers in the healthcare sector.
- Abbott Laboratories (NYSE: ABT): Hold with a $1.12 recent quarter EPS
- Amgen (NASDAQ: AMGN): Moderate Buy with a $1.32 recent quarter EPS
- Bristol-Myers Squibb (NYSE: BMY): Hold with a $0.58 recent quarter EPS
- GlaxoSmithKline (NYSE: GSK): Hold with a $1.01 recent quarter EPS
The large-cap pharmaceutical company's industry has seen price/earnings growth of 2.9% during the current fiscal year.
Finally, a description of the company's main areas of operation: Pfizer is a global pharmaceutical company which develops and manufactures prescription medications for humans and animals.
Take Action:
There is your peek into Pfizer's upcoming earnings numbers, including some competitors to watch around the time of the announcement. Check back in with us after the announcement for a full recap of the announcement. In the meantime, here are some links to explore today.
- To see up-to-date news on Pfizer, click here
- To see other trading ideas, click here
- To see other company earnings recaps, click here
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!